Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic's Q1 Topline Tumbles Due To Global IT Crash

Executive Summary

Medtronic first quarter sales fell short of expectations with the company reporting worldwide revenue of $7.4bn, lagging analysts predicted revenue of $7.45bn. The medtech giant said its top line had been impacted by a global meltdown of company IT systems on June 19 that affected the ability to process, ship and manufacture orders for a week.

You may also be interested in...



Cardiovascular Divisions Boost Medtronic's FYQ2 Top-Line As Hurricane Recovery Continues

Medtronic's revenue of $7.1bn for the second fiscal quarter of 2018 was down 4% year-over-year on an as-reported basis, but up 4% on a comparable constant-currency basis. –It would have been even greater if not for the hurricane that hindered manufacturing operations in Puerto Rico, the company reported Nov 21.

Medtronic Computer Crash To Have Limited Impact

Despite a major a computer crash, Medtronic is confident it will meet its revenue growth projections for the first quarter. The company also says there is currently no indication the crash was the result of an outside agent such as the recent WannaCry and Petya worms.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel